Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 10(64), 2020

DOI: 10.1128/aac.00825-20

Links

Tools

Export citation

Search in Google Scholar

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production

Journal article published in 2020 by Natalia Fintelman-Rodrigues, Carolina Q. Sacramento, Carlyle Ribeiro Lima, Franklin Souza da Silva ORCID, André C. Ferreira, Mayara Mattos, Caroline S. de Freitas, Vinicius Cardoso Soares ORCID, Suelen da Silva Gomes Dias, Jairo R. Temerozo, Milene D. Miranda ORCID, Aline R. Matos, Fernando A. Bozza ORCID, Nicolas Carels, Carlos Roberto Alves and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor.